In fact, the CRC cohort had significantly lower expression of PD-L1 (p = 0.0005) compared to the NSCLC cohort despite similar rates of TP53 mutation across both cancers, suggesting that varying mechanisms regulate PD-L1 expression across different tumor types [185]. Here, TP53 is linked to cancer.